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The human monoclonal antibody b12 recognizes a conserved epitope on gp120 that overlaps the CD4 binding
site. b12 has neutralizing activity against diverse human immunodeficiency virus type 1 (HIV-1) strains.
However, we recently reported that b12 sensitivity of HIV-1 envelopes amplified from patient tissues without
culture varied considerably. For two subjects, there was clear modulation of b12 sensitivity, with lymph
node-derived envelopes being essentially resistant while those from brain tissue were sensitive. Here, we have
mapped envelope determinants of b12 resistance by constructing chimeric envelopes from resistant and
sensitive envelopes derived from lymph node and brain tissue, respectively. Residues on the N-terminal flank
of the CD4 binding loop conferred partial resistance. However, a potential glycosylation site at residue N386
completely modulated b12 resistance but required the presence of an arginine at residue 373. Moreover, the
introduction of R373 into b12-sensitive NL4.3 and AD8 envelopes, which carry N386, also conferred b12
resistance. Molecular modeling suggests that R373 and the glycan at N386 may combine to sterically exclude
the benzene ring of b12 W100 from entering a proximal pocket. In summary, we identify residues on either side
of the CD4 binding loop that contribute to b12 resistance in immune tissue in vivo. Our data have relevance
for the design of vaccines that aim to elicit neutralizing antibodies.
The human immunodeficiency virus type 1 (HIV-1) enve-
lope on virions is made of a surface (SU) gp120 and trans-
membrane (TM) gp41 that are assembled as trimeric glycop-
rotein spikes. Binding of CD4 to the trimeric spike induces
conformational changes in gp120 that result in the formation
of a binding site for the coreceptor. The binding of gp120 to
coreceptors then triggers further conformational changes that
release the fusion domain of gp41 and initiate fusion between
virion and host cell membranes (2). gp120 was first crystallized
in a complex with the two N-terminal domains of CD4 and a
human gp120-specific monoclonal antibody (MAb) (17b) (7).
The gp120 construct used to obtain this structure was deleted
for variable loops V1 to V3 and for several potential glycosyl-
ation sites (PGSs). Nevertheless, the structure showed that the
gp120 core consists of an inner domain of gp120 (which would
include the N and C termini of gp120 and sites predicted to
interact with gp41) connected to an outer domain via a “bridg-
ing sheet” composed of four -strands. CD4 binds to a site that
comprises several sites on different gp120 regions that are
brought together on binding into a depression between the
three gp120 domains.
Previously, we reported that CCR5-using, R5 envelopes var-
ied considerably in macrophage tropism (11, 13). For example,
highly macrophage-tropic R5 envelopes were prevalent in
brain tissue of patients with neurological complications includ-
ing dementia but were less frequent in lymph node (LN),
blood, and semen (11, 13). These envelopes were characterized
by their capacity to infect cells via low levels of CD4 (11, 13).
In addition, Dunfee et al. (4) described an envelope polymor-
phism at residue 283 in the C2 part of the CD4 binding site.
Thus, N283 was associated with 41% of envelopes present in
the brain of subjects with HIV-associated dementia and with
only 8% in non-HIV-associated dementia subjects (4). We also
noted that N283 was present in over 50% of highly macro-
phage-tropic envelopes from brain but infrequent in envelopes
from LN, blood, and semen (13). N283 may form a hydrogen
bond with Q40 on CD4 (more readily than the usual T283
residue) and confer a higher gp120:CD4 affinity (4). Nonethe-
less, not all macrophage-tropic R5 envelopes carry N283, and
additional unknown determinants must also exist.
More recently, we have shown that most macrophage-tropic
brain envelopes tested were sensitive to the CD4 binding site
MAb b12, while the majority of non-macrophage-tropic R5
envelopes from LN were resistant. For example, for two sub-
jects, several envelopes amplified from LN tissue were resistant
to b12, while those from brain were sensitive, thus revealing
clear intrapatient and tissue-specific variation in b12 sensitiv-
ity. These results suggested to us that HIV-1 replication in the
brain may result in the evolution of envelopes that carry a
more exposed CD4bs which would contribute to an increased
affinity for CD4 but increase the vulnerability of envelopes to
CD4bs Abs. Moreover, the blood-brain barrier excludes most
immunoglobulin from the brain and may thus provide an ideal
environment for the evolution of such variants.
Several studies show that b12 carries the potential to neu-
tralize diverse HIV-1 isolates (9, 10), while the CD4bs and the
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b12 epitope are under intense investigation as potential can-
didates for vaccines. It is therefore important to understand
how variation in b12 sensitivity arises in vivo and to elucidate
the mechanisms of resistance involved. It will also be critical to
understand how envelope mutations that confer b12 resistance
affect exposure of the b12 epitope and the CD4bs. Here, we
have mapped envelope determinants involved in b12 resistance
by constructing chimeric envelopes from a b12-sensitive brain
envelope and a resistant LN envelope from the same patient.
We show that determinants on the N-terminal flank of the
CD4 binding loop conferred partial resistance to b12. More-
over, a glycosylation site at N386 conferred complete b12 re-
FIG. 1. gp160 amino acid sequence alignment for NA420 envelopes. StuI and Bsu36I restriction sites used to prepare chimeric envelopes occur
after residues Q203 and S364, respectively. Note that residue numbering for envelopes in this figure does not precisely follow HXBc2 numbering,
which is used throughout the text.
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sistance but required the presence of an arginine at residue
373. R373 and N386 are close to the CD4 binding loop and
together appear to sterically prevent the benzene ring on the
side chain of W100 of b12 from penetrating a pocket close to
the two gp120 residues.
MATERIALS AND METHODS
Cells. 293T cells (3) were used to prepare env pseudovirions by transfection.
HeLa TZM-BL cells were used to titrate env pseudovirions and to evaluate
HIV-1 neutralization. HeLa TZM-BL cells express high levels of CD4 and CCR5
and contain -galactosidase and luciferase reporter genes under the control of an
HIV long terminal repeat (14).
Patient tissue samples and molecular constructs of pseudovirions. HIV en-
velopes used here were described previously (11, 13). Envelopes B33, B42, and
LN40 were derived from subject NA420, a heterosexual patient who died of
AIDS with no cognitive impairment and sparse giant-cell encephalitis. Samples
from temporal lobe brain and LN tissue obtained at autopsy were frozen at
80°C, and DNA was extracted as described previously (15). PCR amplification
of complete envelopes from tissue DNA was performed as described previously
(11). NA420 envelope genes were cloned via conserved KpnI restriction sites into
pSVIIIenv (6) and into pBluescript for direct mutagenesis.
Mutagenesis. Site-directed mutagenesis was carried out using the QuikChange
site-directed mutagenesis kit (Stratagene Inc.) using gp160 pBluescript plas-
mids as templates and mutagenic primers to introduce the desired mutations.
The presence of each mutation was confirmed by sequencing. Mutated gp160s
were cloned into pSVIIIenv via conserved KpnI sites.
Production and titration of env pseudovirions. The env pNL4.3 construct
and pSVIIIenv expression vectors were described previously (11, 13). Pseudoviri-
ons carrying patient envelopes were produced by cotransfection of env pSVII-
Ienv with env pNL4.3 into 293T cells using calcium phosphate. Cell superna-
tants carrying pseudovirions were harvested 48 h after transfection, clarified
(1,000  g for 10 min), aliquoted, and stored at 152°C.
Pseudovirions carrying patient-derived envelopes were titrated on HeLa
TZM-BL cells using the long terminal repeat-controlled -galactosidase reporter
gene to identify infected cells as described previously (16). Since env
pseudovirions undergo only a single round of replication, focus-forming units/ml
were estimated by counting individual or small groups of blue-stained cells.
Neutralization and inhibition assays. Neutralization was measured as a re-
duction in -galactosidase reporter gene expression after infection of HeLa
TZM-BL cells with MAb-treated pseudovirions. Two hundred microliters of
HeLa TZM-BL (4  104 cells/ml) was added to each well in 96-well lumines-
cence plates (Corning Inc.) 1 day before neutralization assays. Two hundred
focus-forming units of pseudovirions was incubated with twofold dilutions of b12
for 2 h at 37°C. Fifty microliters of this mixture was incubated with HeLa
TZM-BL cells at 37°C overnight before being removed, and 200 l of growth
medium was added. Seventy-two hours after incubation, the luminescence reac-
tion was initiated by adding 100 l of Beta-Glo (Promega Inc.) with 100 l of
Dulbecco modified Eagle medium (no phenol red) per well. Luminescence was
measured 30 min later. Percent neutralization was defined by the formula (1 
p/n)  100, where p is the mean luminescence value produced in the presence of
b12 MAb and n is the mean luminescence value produced in the absence of b12
MAb (positive control).
ELISA for soluble gp120. Costar 96-well enzyme-linked immunosorbent assay
(ELISA) plates (catalog no. 3690; Corning Inc.) were coated with 250 ng/well of
sheep anti-gp120 Ab D7324 (catalog no. 6205; Cliniqa, Inc.) in phosphate-
buffered saline (PBS). After overnight incubation at 4°C, plates were washed
twice with PBS-0.05% Tween, incubated for 1 h at room temperature (RT) with
blocking solution (3% bovine serum albumin in PBS), and washed four times
with PBS-0.05% Tween. Fifty microliters/well of env pseudovirion dilutions (in
1% bovine serum albumin-PBS-0.02% Tween) was added for 2 h at RT. After 10
washes, appropriate dilutions of b6 and b12 MAbs or QCmix were incubated at
RT for 2 h and washed 10 times. Fifty microliters/well of goat anti-human
immunoglobulin G, F(ab)2 fragment-specific, calf intestinal alkaline phos-
phatase conjugate (Pierce 31312) diluted 1:1,000 in dilution buffer was added to
plates. After 1 h of incubation at 37°C, an AMPAK kit (Argene Inc.; K6200) was
used to detect alkaline phosphatase activity, following kit instructions. Plates
were read at 492 nm after stop solution was added.
PyMol analyses. The structure of HIV-1 gp120 complexed with the broadly
neutralizing CD4 binding site Ab b12 was described by Zhou et al. (17). The
2NY7.pdb file of the gp120:b12 structure was downloaded from the Research
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank web
page.
RESULTS
Envelopes derived from the LN and brain of patient NA420
vary in biological properties. Previously we described five R5
envelopes that were amplified from brain and LN tissue of a
heterosexual HIV-1 patient (NA420) who died of AIDS with
neurological complications (11, 13). The brain-derived R5 en-
velopes were macrophage tropic, and we have shown recently
that they are sensitive to neutralization mediated by the human
MAb b12 (12). In contrast, the LN-derived envelopes infected
macrophages very inefficiently and were resistant to b12. Fig-
ure 1 shows the amino acid alignment for gp120 of these five
envelopes.
Identification of gp120 regions involved in b12 sensitivity
and resistance. Chimeric envelopes were constructed from
B33 and LN40 envelopes in pSVIIIenv (Fig. 2). The LN40
parental construct used here already carried the gp41 region of
B33, greatly simplifying the design of chimeric envelopes. This
LN40 construct had previously been shown to be resistant to
b12-mediated neutralization, while B33 was sensitive.
The sensitivity of the chimeric envelopes to b12 neutraliza-
tion was tested using a single-round pseudovirion infectivity
system (see Materials and Methods). The Stu-V1/V2 LN40 and
Stu-V1/V2 B33 chimeras exchange a region that includes the
V1V2 loops. These chimeric envelopes conferred b12 sensitiv-
ity similar to that conferred by the parental envelopes (Fig. 3),
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V5 gp41
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FIG. 2. Chimeric B33/LN40 envelopes constructed for mapping de-
terminants of b12 sensitivity.
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FIG. 3. Identification of gp120 regions responsible for b12 resis-
tance by using chimeric constructs made from B33 and LN40 enve-
lopes.
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indicating that the V1V2 loops had little effect on b12 sensi-
tivity. The Stu-V1/V2 B33 chimera also shows that determi-
nants that confer resistance to b12 lie in a region of gp120 that
includes the V3, V4, and V5 loops. The Stu-Bsu and Bsu
chimeras split this region into two. The Stu-Bsu chimera is
comprised of B33 which carries a region of LN40 gp120 with
the V3 loop and sequences flanking the N-terminal side of the
CD4 binding loop (1). In the background of B33, this region
conferred partial resistance to b12, conferring a shift in 50%
infective dose from 1.7 to 13.86 g/ml. In contrast, a region of
LN40 comprising the conserved SGGDPE part of the CD4
binding loop and the V4 and V5 loops in a background of B33
(Bsu chimera) conferred optimal resistance to b12.
The role of the Stu-Bsu region of gp120 in b12 resistance.
We next examined the role of the StuI-Bsu36I region of gp120
in conferring partial b12 resistance. This region includes the
V3 loop and the N-terminal flank of the CD4 binding loop and
contains 11 amino acid differences between B33 and LN40
including an N283T change for LN40 in the C2 CD4 binding
site (Fig. 4). The presence of asparagine at residue 283 was
reported to predominate in HIV-1 envelope sequences in brain
tissue of patients with dementia and was associated with an
enhanced macrophage tropism (4). We also reported that
N283 was predominant in envelopes amplified from brain tis-
sue but infrequent in envelopes from LN, blood, and semen
(13). We tested whether the presence of asparagine, threonine,
or isoleucine (the most common residues) at this position (283)
had any effect on b12 sensitivity. B33 mutants carrying N, T, or
I at residue 283 were all sensitive to b12 neutralization, while
LN40 mutants carrying N, T, or I at residue 283 were all
resistant (data not shown). Thus, residue 283 does not affect
b12 sensitivity for the envelopes tested here.
Other amino acid differences between B33 and LN40 in this
region include an alanine-to-serine switch (residue 291) which
confers the presence of a PGS in LN40 and two differences in
the V3 loop (N308H and L315F) (Fig. 4). There are also five
differences (present in both LN40 and LN85) between the end
of the V3 loop and the Bsu36I restriction site including the
substitution of four of five consecutive residues (VFKPSfIFNQP)
flanking the GDPE motif in the CD4 binding loop. We con-
structed mutant versions of B33 carrying various combinations
of the amino acids present in both b12-resistant LN40 and
LN85 but absent in b12-sensitive B33. We first tested B33
mutants that carried SHFE, INQP, or SHFEINQP substitu-
tions (Fig. 4). B33 (SFHE) was only marginally less sensitive to
b12 than was B33 (Fig. 5A). However, B33 (INQP) showed a
marked shift toward b12 resistance, yet it was still more sen-
sitive than the Stu-Bsu chimeric envelope that carries the en-
tire Stu-Bsu region from LN40. B33 (SFHEINQP) combines
eight implicated substitutions and conferred resistance to b12
similar to that conferred by the partially resistant Stu-Bsu
chimeric env. We next investigated the role of residues in the
upstream flank of the CD4 binding loop. B33 mutants carrying
Q, P, QP, NQP, or INQP (residues present in LN40) were
partially resistant to b12, with the QP motif consistently con-
ferring b12 resistance closest to that conferred by the Stu-Bsu
FIG. 4. Amino acid sequence alignment for NA420 envelopes. Amino acids from StuI to the V4 loop are shown. This region covers the residues
identified here as determinants in b12 resistance. StuI and Bsu36I restriction sites occur after residues Q203 and S364, respectively. Note that
residue numbering for envelopes in this figure does not precisely follow HXBc2 numbering, which is used throughout the text.
FIG. 5. Amino acids flanking the CD4 binding loop influence b12
sensitivity. Residues present in the LN40 Stu-Bsu fragment but absent
in B33 were introduced into B33. (A) B33 substitutions were made for
residues on the N-terminal flank of the CD4 binding loop (INQP [Fig.
4]) and for residues upstream (SHFE) or both. Residues on the CD4
binding loop flank confer partial resistance, and this is enhanced by
upstream residues. (B) Residues QP on the CD4 binding loop flank
confer the most resistance. (C) Residues H and F in the V3 loop
combine with CD4 binding loop flanking residues to confer the partial
b12 resistance shown by the Stu-Bsu LN40 fragment.
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chimera (Fig. 5B). Finally, we analyzed B33 carrying INQP and
various combinations of the SFHE substitutions. B33 mutants
that carried V3 loop residues H and F in combination with
INQP conferred resistance to b12 similar to that conferred by
the Stu-Bsu chimera (Fig. 5C). In summary, QP substitutions
located in the upstream flank of the CD4 binding loop confer
partial resistance to b12. However, this resistance is enhanced
by upstream residues, 308H and 317F, within the V3 loop.
A PGS (N386) in the C-terminal region of gp120 confers
optimal b12 resistance but depends on R373. The sensitivity of
chimeric B33/LN40 envelopes to b12 implicated a region from
the Bsu36I restriction site to the gp120/gp41 junction for op-
timal b12 resistance. In this region, there are several differ-
ences in the V4 and V5 loops between B33 and LN40. How-
ever, we focused on differences closest to the CD4 binding loop
(Fig. 4) including K/R, D/N, and Q/K substitutions at residues
373, 386, and 389, respectively. The D386N change results in
the loss of a PGS in B33. The PGS at 386 was recently impli-
cated in b12 sensitivity and macrophage tropism (5).
B33 mutants carrying double (K373R/D386N, D386N/
Q389K, or K373R/Q389K) or triple (K373R/D386N/Q389K)
substitutions were tested for b12 sensitivity. K373R/Q389K
had no effect on b12 sensitivity (Fig. 6A). However, while
D386N/Q389K conferred a small shift toward resistance,
K373R/D386N and K373R/D386N/Q389K conferred complete
resistance. These observations implicate the PGS at residue
386; however, optimal b12 resistance was observed only when
N386 was present together with R373.
We next tested B33 mutants K373R and D386N as well as a
triple mutant which contained K373R/D386N (which confer
b12 resistance) but also T388V to abrogate the PGS at N386
(Fig. 6B). K373R alone had no effect on b12 sensitivity. The
D386N substitution introduces the PGS at residue 386 and
conferred a modest shift toward b12 resistance. However,
while the K373R/D386N mutant conferred optimal b12 resis-
tance, the triple mutant that carried T388V to abrogate N386
as a PGS was sensitive to b12. These observations confirm that
the glycan at N386 rather than the asparagine residue itself is
responsible for b12 resistance. Intriguingly, optimal b12 resis-
tance conferred by the N386 glycosylation site required the
presence of an arginine at residue 373.
The mutants described above were all based on the B33
envelope and have implicated a PGS at residue 386 as impor-
tant for b12 resistance. We next substituted T388 for alanine in
b12-resistant LN40 env, leaving the N386 intact but eliminating
the PGS. T388A rendered LN40 sensitive to b12, confirming
the role of the N386 glycan as a critical determinant for LN40
resistance to b12 (Fig. 6C).
Envelopes that carry the N386 glycosylation site may be
sensitive or resistant to b12 depending on residue 373. NA420
B42 envelope is from the same patient as are the B33 and
LN40 envelopes. However, unlike B33, B42 carried a PGS at
N386 and yet was sensitive to b12. Results presented above
show that B33 required the presence of an arginine residue at
373 in addition to N386 for optimal resistance to b12. We
therefore introduced an arginine at residue 373 in B42. M373R
rendered B42 resistant to b12 (Table 1) and confirmed the
importance of residue 373 for b12 resistance.
To further test the role of residue 373, we prepared LN40
mutants carrying M, T, or K (M and T are the most common
residues) at residue 373 and B33 mutants carrying M, T, or R
FIG. 6. Resistance to b12 is conferred by a PGS at residue 386 but
is modulated by the residue at 373. (A) Double and triple B33 mutants
carrying substitutions at 373, 386, or 389. The combination of R373
and N386 is required for optimal resistance to b12. (B) Neither R373
nor N386 alone confers b12 resistance. However, b12 resistance con-
ferred by R373/N386 is abrogated if the PGS at N386 is eliminated by
a T388V substitution. Thus, R373 and the glycan at N386 are required
for maximal b12 resistance. (C) T388A in LN40 retains the asparagine
at 386 but eliminates the glycosylation signal. T388A confers sensitivity
to b12 for LN40.
TABLE 1. Role of envelope residue 373 in b12 neutralization
env wt or mutantresidues (373/386) IC50
a (g/ml)
B42 MN (wt) 1
RN 50
B33 KD (wt) 1.7
MN 1.7
TN 2.5
KN 6.1
RN 50
LN40 RN (wt) 50
MN 2.8
TN 3.7
KN 3.6
a IC50, 50% inhibitory concentration.
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(in conjunction with a PGS at N386). M and T represent the
most prevalent residues at position 373. Only a combination of
both R373 and N386 conferred optimal b12 resistance in both
B33 and LN40 envelopes (Table 1). Combinations of M373 or
T373 with N386 perhaps conferred a marginal shift in resis-
tance compared to that conferred on B33, while K373/N386
conferred a modest shift toward resistance (Table 1).
We next introduced R373 into NL4.3 and macrophage-
tropic AD8 envelopes, both of which are sensitive to b12 de-
spite carrying PGSs at N386. AD8 usually has M at 373, while
NL4.3 has T373. The presence of R373 rendered both NL4.3
and AD8 resistant to b12 (Fig. 7), indicating that variation at
residue 373 can completely modulate b12 resistance for enve-
lopes unrelated to B33 and LN40. Finally, we introduced a
valine residue at position 388 into the AD8 envelope that
already carried R373. This mutant thus carries R373 and N386;
however, N386 is no longer a potential glycosylation signal.
This AD8 mutant was sensitive to b12 (Fig. 7, top panel),
confirming that R373 and the glycan at N386 act together in
AD8 to confer b12 resistance.
Residue 373 is adjacent to N386, and together these deter-
minants may sterically block the formation of a b12:env com-
plex. The structure of the b12:gp120 complex was previously
solved using gp120 from b12-sensitive HXBc2, which carries a
threonine at 373 and a PGS at N386 (17). Our studies show
that R373 was required with a PGS at N386 to protect B33
against b12, while K, T, or M at 373 failed to protect. Residues
373 and 386 are proximal in all the gp120 structures published
to date including the unliganded simian immunodeficiency vi-
rus gp120 (1), gp120 complexed with CD4 and MAb 17b (7),
and the gp120/b12 complex (17). Figure 8 shows the proximity
of residues 373 and 386 in the gp120/b12 complex and reveals
how the benzene ring of the W100 side chain on b12 targets a
pocket surrounded by the side chain of residue 373 and the
N386 glycan. Using the PyMol program, we tried to introduce
an arginine at residue 373. However, arginine, which has a
longer side chain than that of K, T, or M, does not fit into the
b12:gp120 structure without nonpermissible interactions with
surrounding residues (not shown). These observations strongly
suggest that a combination of the glycan at N386 and the side
chain of R373 sterically prevents an interaction with W100 on
b12 with gp120 and the formation of a gp120/b12 complex (17).
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FIG. 7. R373 and the N386 glycan confer b12 resistance to NL4.3
and AD8. The introduction of an arginine at residue 373 conferred b12
resistance on both AD8 and NL4.3, both of which carry a PGS at N386.
A valine was next introduced at residue 388 in R373 AD8 to elimi-
nate the PGS at N386. This mutant was sensitive to b12 (top panel),
showing that R373 and the N386 glycan act together to confer b12
resistance on NL4.3 and AD8.
FIG. 8. Proximal gp120 residues R373 and N386 cooperate to steri-
cally block b12 binding and neutralization. Residues 373 and 386 are
proximal in the published structure of b12 complexed with gp120 as
shown (17). In this reported structure, residue 373 is a threonine. The
introduction of an arginine residue at this position using the PyMol
program is not possible due to the steric limitations of residues sur-
rounding this pocket. The presence of R373 and N386 is therefore
likely to sterically exclude the benzene ring of b12 W100 from this
pocket.
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R373 and N386 reduce binding of b12 to monomeric gp120.
The structure of the b12:gp120 complex strongly suggests that
the combination of R373 and the N386 glycan acts to prevent
binding of b12. We next evaluated whether R373/N386 or
combinations of these and other residues at these positions
influence binding of b12 to monomeric, detergent-treated
gp120. To test this, solubilized monomeric gp120, present in
pseudovirions treated with 0.02% Tween 20, was captured onto
96-well ELISA plates using sheep Abs that recognize the C
terminus of gp120. We tested whether b12, b6, or a mix of
HIV-1 human sera (QCmix) could bind captured gp120. Both
QCmix and b6 bound B33 wild type (wt) (K373/D386) and
mutants K373/N386, M373/N386, T373/N386, and R373/N386
to similar levels (Fig. 9, top panels). b12 also bound to B33 wt
and all mutants, although binding to R373/N386 was slightly
less efficient than that for B33 wt gp120 and other B33 mutants.
For LN40, the QCmix and b6 bound wt and mutants to similar
levels except for the K373/N386 mutant, which was presumably
present at lower concentrations in the pseudovirion prepara-
tion (Fig. 9, bottom panels). b12 also bound LN40 wt and each
mutant, with slightly more efficient binding to the M373/N386
and T373/N386 mutants than to LN40 wt, which carried R373/
N386. These observations show that R373 and N386 together
reduce binding of b12 to monomeric gp120 solubilized in
Tween 20. However, this modest reduction in b12 binding
cannot explain the more complete resistance observed in neu-
tralization assays. These observations suggest that 0.05%
Tween 20 may allow b12 better access to the gp120 pocket
flanked by residues 373 and 386 and/or that the trimeric form
of functional envelope spikes contributes to the shielding of
the b12 epitope by R373 and N386.
DISCUSSION
We have studied envelope determinants that confer natural
resistance to b12, a CD4bs MAb. We investigated envelopes
previously amplified by PCR without culture from brain and
LN tissue of the same patient (NA420). The brain-derived
envelopes were sensitive to b12, while those from LN were
resistant (12). We show that HIV-1 sensitivity to b12 can be
completely modulated by the presence of a glycan at residue
386, although resistance required the presence of an arginine
at residue 373. Together, R373 and the N386 glycan may steri-
cally prevent the benzene ring of b12 W100 from penetrating a
pocket proximal to these two residues. Nevertheless, b12
bound to monomeric, detergent-solubilized gp120 that carried
R373/N386, indicating that the envelope trimer may also play
a role in the protection of this epitope. The introduction of
R373 into b12-sensitive envelopes NL4.3 and AD8 (which con-
tain PGSs at N386) rendered both resistant to b12, confirming
that this mechanism of b12 resistance transfers to unrelated
envelopes. Our data extend the recent report by Dunfee et al.,
also using brain-derived envelopes, that showed a modest in-
fluence of N386 for b12 sensitivity (5). Nonetheless, it is clear
that many HIV-1 envelopes (either b12 resistant or sensitive)
carry a PGS at N386, indicating that the presence of N386
alone does not predict b12 sensitivity. Interestingly, in the
crystal structure of the gp120:b12 complex (17), the glycan at
N386 contacts b12, even though we show here that envelopes
lacking N386 are sensitive to b12. Thus, the glycan at N386 is
not required for b12 binding or neutralization. On the HIV
sequence database (http://www.hiv.lanl.gov/content/sequence
/HIV/mainpage.html) methionine and threonine (which do not
confer b12 resistance) are the most common residues at posi-
tion 373. Arginine and lysine (residues at 373 for LN40 and
B33, respectively) have larger side chains than methionine and
threonine. These residues are rare in the database, suggesting
that they may adversely affect viral fitness. K373 in combina-
tion with N386 conferred partial resistance on B33 (Table 1).
However, the larger side chain of R373 together with the N386
glycan may fill the proximal pocket and generally confer b12
FIG. 9. b12 binding to captured, solubilized, monomeric gp120. Serial dilutions of env pseudovirions were treated with Tween 20 and captured
onto a solid phase as described in Materials and Methods. The capacities of b6, b12, and QCmix to bind captured B33 or LN gp120 were evaluated
by ELISA. Generally b6 and QCmix bound to captured B33 or LN40 gp120s at equivalent levels. Binding of b12 to B33, LN40, and mutants that
carried K, R, M, or T373 in combination with N386 varied. Generally, M and T373 (with N386) bound b12 better than did K or R373. Nevertheless,
this modest variation in binding b12 does not explain the more complete modulation of neutralization sensitivity.
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resistance, as shown for AD8, NL4.3, B33, B42, and LN40
envelopes.
Our data also show a partial but significant shift in b12
sensitivity that is conferred by residues on the N-terminal flank
of the CD4 binding loop. This region is variable and may play
a role in the exposure of the CD4 binding loop, perhaps by
altering its orientation. Interestingly, residues in the V3 loop
also contributed to this partial resistance to b12. It is therefore
possible that the V3 loop in the unliganded envelope lies close
enough to the CD4 binding loop to influences its exposure,
although other mechanisms are also tenable. Recently, Lynch
et al. reported that a single change in the V3 loop of a clade C
envelope conferred exposure of the CD4 binding site and sen-
sitivity to soluble CD4 (8). These observations also suggest a
role for the V3 loop in protecting the CD4 binding site. Using
the same B33 and LN40 envelopes described here, we have
recently investigated envelope determinants that confer R5
macrophage tropism. We showed that determinants affecting
R5 macrophage tropism essentially overlap with those re-
ported here for b12 sensitivity. However, R373 and N386 have
only a modest influence on R5 macrophage tropism, while the
determinants on the N-terminal flank of the CD4 binding loop
are more critical (M. J. Duenas-Decamp et al., unpublished
observations). Nevertheless, together these results strongly
support a hypothesis where the evolution of envelopes in the
brain that confer enhanced macrophage infection directly re-
sults in increased sensitivity to neutralizing Abs that target the
CD4bs. Conversely, replication in immune tissues such as LNs
selects for variants where the CD4bs is protected from CD4bs
Abs such as b12. The variation in b12 sensitivity reported here
and in a more extensive study (12) thus supports the possibility
that Abs recognizing the CD4bs or proximal epitopes are
present in vivo and are an important selective force that im-
pacts on R5 macrophage tropism and neutralization sensitivity.
In summary, we describe important mechanisms exploited
by HIV-1 to protect the CD4 binding site from neutralizing
Abs. We have identified determinants on the N-terminal flank
of the CD4 binding loop that partially modulate b12 sensitivity
and likely influence the exposure or orientation of this loop. In
addition, we show that a combination of R373 and a glycosyl-
ation site at N386 acts to sterically block W100 of b12 pene-
trating a pocket proximal to these two residues. N-linked gly-
cans have been reported to protect against neutralizing Abs.
However, our data show that additional envelope determinants
modulate the capacity of glycans to provide such protection.
Our results greatly improve our understanding of envelope
sensitivity to b12 neutralization and may lead to improved ways
to design optimal CD4 binding site structures for vaccines.
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